The biopharmaceutical sector is transitioning from reactive off-line quality control to a proactive quality by design (QbD) framework. Process analytical technology (PAT) enables this shift through ...
Since 2008, downstream purification issues have become progressively more acute problems for biomanufacturers. But that’s begun to change this year, according to results from BioPlan Associates’ 9th ...
In industries relying on up-to-the-minute insights, interruptions disrupt crucial processes, hindering timely responses to market changes and the accuracy of analytical outcomes. This can lead to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results